Compugen Ltd. - Ordinary Shares (CGEN) News
Filter CGEN News Items
CGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CGEN News Highlights
- CGEN's 30 day story count now stands at 8.
- Over the past 16 days, the trend for CGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about CGEN are PRE, AZN and EVGN.
Latest CGEN News From Around the Web
Below are the latest news stories about COMPUGEN LTD that investors may wish to consider to help them evaluate CGEN as an investment opportunity.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & MoreCompugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively. |
Gilead (GILD), Compugen Collaborate for Immunotherapy ProgramGilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program. |
Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week aloneThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right... |
Why Are Stocks Up Today?Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday! |
Why Is Compugen (CGEN) Stock Up 189% Today?Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning! |
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract CancerCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig. Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. The |
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 BiologyCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to tre |
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy ProgramFOSTER CITY, Calif. & HOLON, Israel, December 19, 2023--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program |
7 Promising Penny Stocks With the Potential to Defy ExpectationsYou know you want it. |